Cardiac Surgery

Effects of Octaplas and FFP on hemostasis and fibrinolysis in complex coagulopathy following
open‐heart surgery1

  • Prospective open-label study in post-operative, open heart surgery patients who required plasma transfusion for acute bleeding or for risk of bleeding
  • Study was not powered to detect a difference in efficacy
STUDY OBJECTIVES: ASSESS EFFICACY AND TOLERABILITY OF
OCTAPLAS IN PATIENTS UNDERGOING CARDIAC SURGERY
OctaplasFFP
N (Male/Female)36 (20/16)31 (17/14)
Median age (range)69.5 years (34-79)72 years (55-86)
Dosage (mL)600600
Median dosage (range)8.5 mL/kg (5.5-14.2)8.5 mL/kg (5.5-12.2)

Conclusions

Clinical hemostasis evaluation revealed no significant difference between Octaplas and FFP.  No adverse reactions were reported.

icon-clip-board Created with Sketch.

The safety and efficacy of Octaplas was studied in adult patients with coagulopathies due to liver disease or liver transplantation.

Learn More
Reference:
  1. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002; 82:9-14.